clinical trial · NCT06258304
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
GigaGen, Inc.·phase1·recruiting·n = 60
Advanced or Metastatic Solid Tumor MalignanciesGIGA-564GIGA-564
brief summary
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
started
May 8, 2024
primary completion
Apr 1, 2026
completion
Nov 1, 2027
last updated
Apr 10, 2025
official title
A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol